Show Me the Data: Translating Clinical and Practice-Based Evidence on Oral SERDs Into Everyday Care for HR+/HER2– Metastatic Breast Cancer

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Reshma L. Mahtani, DO; Kamel Abou Hussein, MD; and Irene Kang, MD; discuss how to translate clinical and real-world evidence regarding oral selective estrogen receptor degraders (SERDs) and targeted combination therapies into everyday clinical practice for managing hormone receptor–positive/HER2-negative metastatic breast cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Apply clinical trial and real-world evidence to select and sequence oral SERDs after progression on a CDK4/6 inhibitor plus endocrine therapy
• Develop treatment strategies for dual resistance, integrating evidence for targeting the PI3K/AKT pathway in patients with co-occurring ESR1 and PIK3CA pathway alterations

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from Stemline Therapeutics, Inc.

Chair:

Reshma L. Mahtani, DO

Medical Oncologist
Chief of Breast Medical Oncology
Baptist Health Miami Cancer Institute
Miami, FL

Disclosures: Consultant: Agendia, Arvinas, AstraZeneca, Daiichi Sankyo, Eisai, Genentech, Hologic, Lilly, Novartis, Pfizer, Sermonix, Stemline; Grant/Research Support: Gilead Sciences

Faculty:

Kamel Abou Hussein, MD

Assistant Professor of Medicine
Cooper Medical School of Rowan University
Co-Director, Janet Knowles Breast Cancer Center
Cooper University Health Care
Camden, NJ

Disclosures: Advisor, Consultant, Fee for Service Recipient: AstraZeneca; Speakers Bureau: Lilly

Irene Kang, MD

Medical Director, Women’s Health Breast Oncology
Assistant Professor, Division of Medical Oncology and Therapeutics Research
City of Hope Orange County
Irvine, CA

Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AstraZeneca, BioNTech, Caris Life Sciences, Daiichi Sankyo, Gilead, Novartis, Pfizer, Stemline Therapeutics

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including information on deciding between single-agent versus combination therapy considering the toxicities and the clinical versus real-world data on progression-free survival, go to https://www.gotoper.com/smtd26serds-activity.

Release Date

April 21, 2026

Expiration Date

April 21, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.